These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 8780524)

  • 1. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T; Petrash JM
    Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized aldose reductase: in vivo factor not in vitro artifact.
    Grimshaw CE; Lai CJ
    Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sorbinil trap: a predicted dead-end complex confirms the mechanism of aldose reductase inhibition.
    Bohren KM; Grimshaw CE
    Biochemistry; 2000 Aug; 39(32):9967-74. PubMed ID: 10933817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
    Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK
    Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
    Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
    Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of non-enzymatic glycation on recombinant human aldose reductase.
    Yamaoka T; Oda A; Bannai C; Itakura M; Yamashita K
    Diabetes Res Clin Pract; 1995 Mar; 27(3):165-9. PubMed ID: 7555597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of aldose reductase by S-nitrosoglutathione.
    Chandra A; Srivastava S; Petrash JM; Bhatnagar A; Srivastava SK
    Biochemistry; 1997 Dec; 36(50):15801-9. PubMed ID: 9398310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
    Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
    Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
    Barski OA; Gabbay KH; Bohren KM
    Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of sulfhydryl residues in aldose reductase-inhibitor interaction.
    Bhatnagar A; Liu S; Das B; Srivastava SK
    Mol Pharmacol; 1989 Dec; 36(6):825-30. PubMed ID: 2513474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does sorbinil bind to the substrate binding site of aldose reductase?
    Liu SQ; Bhatnagar A; Srivastava SK
    Biochem Pharmacol; 1992 Dec; 44(12):2427-9. PubMed ID: 1472112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
    Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
    J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity.
    Kolb NS; Hunsaker LA; Vander Jagt DL
    Mol Pharmacol; 1994 Apr; 45(4):797-801. PubMed ID: 8183257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex.
    Sugiyama K; Chen Z; Lee YS; Kador PF
    Biochem Pharmacol; 2000 Feb; 59(4):329-36. PubMed ID: 10644040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of human aldehyde reductase: characterization of the active site pocket.
    Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
    Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distribution of aldose reductase and aldehyde reductase II in different regions of bovine lens.
    Liu S; Das B; Srivastava SK
    Lens Eye Toxic Res; 1989; 6(3):415-30. PubMed ID: 2518623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor.
    Kuruvilla R; Eichberg J
    J Neurochem; 1998 Aug; 71(2):775-83. PubMed ID: 9681469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.